Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S ("Stenocare" or the "Company") began on January 07 the subscription period for investors to subscribe for new shares at a discounted price of DKK 0.50 each. This is a time limited offer until January 20, 2025 - however some banks, including Nordnet, have a shorter deadline on Monday January 13. Shareholders and new investors interested in this offer should check the deadline with their bank.
Stenocare has announced a time limited offer to subscribe for new shares in the Company at a discounted price of DKK 0.50 per share. The Company is seeking to raise between DKK 9.1 million and DKK 20.2 million to execute the STENOCARE 3.0 strategy.
All the details are available on the investor homepage: https://stenocare.com/share-issue-2025/
How the offer works?
This offer is available until January 20, 2025, at 5.00 P.M. CET, and there are following ways to access the discounted price:
- Existing shareholders have received a notification/email from their bank, where their Stenocare shares are kept. Follow the instructions from the bank to use your subscription rights to purchase the new shares.
- New investors should use the online subscription form in their bank or use the official Subscription Form to instruct their bank to subscribe for the offer.
To read the official announcement of the conditional rights issue: https://stenocare.com/investor-relations/announcements/3B051C92836EB553/
Who are Stenocare?
Stenocare is a Danish company that has specialised in trading with prescription-based medical cannabis products. The Company has sales activities in 6 different countries with medical cannabis products approved for sales by the local medicine agencies. Stenocare has just launched a new and innovative product, called ASTRUM 10-10, that has the potential to revolutionise the medical cannabis industry. This new patented product has been approved for sales in Germany, Australia and Norway.